Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Anna Truini, Poliana Santos Pereira, Alberto Cavazza, Paolo Spagnolo, Sofia Nosseir, Lucia Longo, Agita Jukna, Filippo Lococo, Giada Vincenzi, Giuseppe Bogina, Marcello Tiseo & Giulio Rossi. (2015) Classification of different patterns of pulmonary adenocarcinomas. Expert Review of Respiratory Medicine 9:5, pages 571-586.
Read now
Read now
Sara Pilotto, Umberto Peretti, Silvia Novello, Giulio Rossi, Michele Milella, Matteo Giaj Levra, Ludovica Ciuffreda, Francesco Massari, Matteo Brunelli, Giampaolo Tortora & Emilio Bria. (2013)
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine
. Expert Opinion on Pharmacotherapy 14:5, pages 597-608.
Read now
Read now
Sai-Hong Ignatius Ou, Jackie Tan, Yun Yen & Ross A Soo. (2012) ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Review of Anticancer Therapy 12:4, pages 447-456.
Read now
Read now
Sai-Hong Ignatius Ou. (2012) Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer. Expert Review of Anticancer Therapy 12:2, pages 151-162.
Read now
Read now
Articles from other publishers (18)
Shun Lu, Qing Zhou, Xiaoqing Liu, Yingying Du, Yun Fan, Ying Cheng, Jian Fang, You Lu, Cheng Huang, Jianying Zhou, Yong Song, Kai Wang, Hongming Pan, Nong Yang, Juan Li, Gongyan Chen, Jianhua Chang, Jiuwei Cui, Zhe Liu, Chunxue Bai, Helong Zhang, Huadong Zhao, Kaiting Zhang, Gerson Peltz, Heyan Li & Yi-Long Wu. (2022) Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China. Journal of Thoracic Oncology 17:6, pages 816-826.
Crossref
Crossref
Gabriele Colozza, Yasaman Jami-Alahmadi, Alyssa Dsouza, Nydia Tejeda-Muñoz, Lauren V. Albrecht, Eric A. Sosa, James A. Wohlschlegel & Edward M. De Robertis. (2020) Wnt-inducible Lrp6-APEX2 interacting proteins identify ESCRT machinery and Trk-fused gene as components of the Wnt signaling pathway. Scientific Reports 10:1.
Crossref
Crossref
Hind Berradi, Houda Kaanane, Nadia El Kadmiri & Sellama Nadifi. (2018) Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. Gene Reports 11, pages 196-204.
Crossref
Crossref
Zheng Wang, Gang Cheng, Xiaohong Han, Xinlin Mu, Yuhui Zhang, Di Cui, Chang Liu, Li Zhang, Zaiwen Fan, Lingyun Ma, Li Yang, Jing Di, David S. Cram, Yuankai Shi & Dongge Liu. (2017) Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma. The Journal of Molecular Diagnostics 19:1, pages 169-181.
Crossref
Crossref
Sebnem Ozemri Sag, Ozlem Gorukmez, Mehmet Ture, Orhan Gorukmez, Adem Deligonul, Serdar Sahinturk, Ali Topak, Tuna Gulten, Ender Kurt & Tahsin Yakut. (2016) Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. SpringerPlus 5:1.
Crossref
Crossref
Zilan Song, Zongjun Xia, Yinchun Ji, Li Xing, Yinglei Gao, Jing Ai, Meiyu Geng & Ao Zhang. (2016) An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core. European Journal of Medicinal Chemistry 118, pages 244-249.
Crossref
Crossref
Cecilia Bozzetti, Rita Nizzoli, Marcello Tiseo, Anna Squadrilli, Costanza Lagrasta, Sebastiano Buti, Donatello Gasparro, Daniele Zanoni, Maria Majori, Massimo De Filippo, Francesca Mazzoni, Cristina Maddau, Nadia Naldi, Gabriella Sammarelli, Caterina Frati, Carmine Pinto & Andrea Ardizzoni. (2015)
ALK
and
ROS1
rearrangements tested by fluorescence
in situ
hybridization in cytological smears from advanced non-small cell lung cancer patients
. Diagnostic Cytopathology 43:11, pages 941-946.
Crossref
Crossref
Stephanie A. HowardMichael H. RosenthalJyothi P. JagannathanKatherine M. KrajewskiAtul B. ShinagareNikhil H. RamaiyaSree Harsha Tirumani. (2015) Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. American Journal of Roentgenology 204:5, pages 919-932.
Crossref
Crossref
Giulio Rossi, Alberto Cavazza, Luisella Righi, Giuliana Sartori, Alessandra Bisagni, Lucia Longo, Giuseppe Pelosi & Mauro Papotti. (2014) Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. International Journal of Surgical Pathology 22:5, pages 401-407.
Crossref
Crossref
Claire Wynne, Elisa Lazzari, Siobhán Smith, Eoghan M. McCarthy, Joan Ní Gabhann, Lara E. Kallal, Rowan Higgs, Sally Ann Cryan, Christine A. Biron & Caroline A. Jefferies. (2014) TRIM68 Negatively Regulates IFN-β Production by Degrading TRK Fused Gene, a Novel Driver of IFN-β Downstream of Anti-Viral Detection Systems. PLoS ONE 9:7, pages e101503.
Crossref
Crossref
Jinghui Wang, Yujie Dong, Yiran Cai, Lijuan Zhou, Shafei Wu, Guimei Liu, Dan Su, Xi Li, Na Qin, Jingying Nong, Hongyan Jia, Quan Zhang, Jing Mu, Xuan Zeng, Haiqing Zhang, Shucai Zhang & Zongde Zhang. (2014) Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. Journal of Cancer Research and Clinical Oncology 140:3, pages 453-460.
Crossref
Crossref
Fredika M Robertson, Emanuel F Petricoin III, Steven J Van Laere, Francois Bertucci, Khoi Chu, Sandra V Fernandez, Zhaomei Mu, Katherine Alpaugh, Jianming Pei, Rita Circo, Julia Wulfkuhle, Zaiming Ye, Kimberly M Boley, Hui Liu, Ricardo Moraes, Xuejun Zhang, Ruggero DeMaria, Sanford H Barsky, Guoxian Sun & Massimo Cristofanilli. (2013) Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus 2:1.
Crossref
Crossref
Rolf Stahel, Solange Peters, Paul Baas, Elisabeth Brambilla, Federico Cappuzzo, Dirk De Ruysscher, Wilfried Ernst Erich Eberhardt, Enriqueta Felip, Dean Fennell, Antonio Marchetti, Luis Paz-Ares & Alex A. Adjei. (2013) Strategies for improving outcomes in NSCLC: A look to the future. Lung Cancer 82:3, pages 375-382.
Crossref
Crossref
Mario Bavieri, Marcello Tiseo, Sylvie Lantuejoul, Anne McLeer-Florin, Anna Lasagni, Riccardo Fantini & Giulio Rossi. (2018) Fishing for ALK with immunohistochemistry may predict response to crizotinib. Tumori Journal 99:5, pages e229-e232.
Crossref
Crossref
Solange Peters, Miquel Taron, Lukas Bubendorf, Fiona Blackhall & Rolf Stahel. (2013) Treatment and detection of ALK-rearranged NSCLC. Lung Cancer 81:2, pages 145-154.
Crossref
Crossref
Sai-Hong Ignatius OuCynthia Huang BartlettMari Mino-KenudsonJean Cui & A. John Iafrate. (2012)
Crizotinib for the Treatment of
ALK
-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
. The Oncologist 17:11, pages 1351-1375.
Crossref
Crossref
Javier Munoz & Razelle Kurzrock. (2012) Targeted therapy in rare cancers—adopting the orphans. Nature Reviews Clinical Oncology 9:11, pages 631-642.
Crossref
Crossref
Victoria C. Pham, Robert Pitti, Veronica G. Anania, Corey E. Bakalarski, Daisy Bustos, Suchit Jhunjhunwala, Qui T. Phung, Kebing Yu, William F. Forrest, Donald S. Kirkpatrick, Avi Ashkenazi & Jennie R. Lill. (2012) Complementary Proteomic Tools for the Dissection of Apoptotic Proteolysis Events. Journal of Proteome Research 11:5, pages 2947-2954.
Crossref
Crossref